International journal of cardiology
-
Letter Case Reports
Neonatal life-threatening arrhythmia responding to lidocaine, a probable LQTS3.
Intrauterine and neonatal manifestations of congenital long QT syndrome (LQTS) are associated with a high cardiac risk. We present a newborn, with antecedents of intrauterine premature ventricular contractions, showing in his surface electrocardiogram (ECG): a QTc of 0.69 ms, 2:1 atrioventricular block, autolimited episodes of ventricular tachycardia and Torsade de Pointes. ⋯ Lidocaine was substituted for oral mexiletine, and esmolol for propranolol. During the follow-up the patient has remained asymptomatic under therapy with propranolol and mexiletine.
-
There are a number of definitions available for the diagnosis of the metabolic syndrome (MetS). The MetS-associated increase in cardiovascular disease (CVD) risk may depend on the definition used. ⋯ CVD prevalence was increased in the presence of MetS irrespective of the definition used. However, this increase was more pronounced when the NCEP-ATP-III and AHA/NHLBI criteria were implemented compared with the IDF definition. Furthermore, the IDF definition included a large proportion of subjects who did not have increased CVD prevalence compared with the whole study population. These findings may have implications regarding which definition should we use to diagnose the MetS.
-
We studied three patients who had orthodromic atrioventricular reentrant tachycardia (AVRT) using left lateral accessory pathway (AP), with difficulty in identifying the earliest site of retrograde atrial activation. ⋯ In AVRT that has a long VA interval and difficulty in identifying the earliest site of retrograde atrial activation, two different mechanisms existed (mitral isthmus block and conduction through CS musculature). Careful mapping of double atrial potentials and continuous VA activation at the left lateral mitral annulus is essential for determination of a successful ablation site.
-
Review Meta Analysis Comparative Study
The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.
Individuals with chronic kidney disease are at high risk for cardiovascular disease and have a high prevalence of hyperlipidemia. Lipid-lowering therapy may help patients with renal disease reduce their risk for cardiovascular events. ⋯ The results of this pooled analysis indicate that fluvastatin is safe and effective for reducing cardiac death and nonfatal myocardial infarction in patients with moderate to severe renal insufficiency. Fluvastatin did not reduce the rate of coronary intervention procedures.
-
The partial pressure of end-tidal carbon dioxide production (P(ET)CO2) at ventilatory threshold (VT) has been shown to be strongly correlated with cardiac output during exercise in patients with heart failure (HF), but few data are available regarding its prognostic utility. ⋯ These results indicate that P(ET)CO2 during CPX is a significant predictor of cardiac-related events in patients with HF. Clinical assessment of this variable in patients with HF undergoing CPX may therefore be warranted.